跳至主要内容
临床试验/CTRI/2017/08/009318
CTRI/2017/08/009318已完成2 期

Impact of neoadjuvant chemotherapy on organ preservation in muscle invasive urinary bladder carcinoma

ONE0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
ONE
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Muscle invasive bladder carcinoma,
  • 2. Stage T2-T4, N0- N1,M0according to AJCC 2010 Staging.
  • 3. Karnofsky Performance Status scale(KPS) >70.
  • 4. All patients were explained about the protocol and a written informed consent was obtained.

排除标准

  • 1. Non muscle invasive bladder carcinoma / Metastatic disease.
  • 2. KPS <70
  • 3. Significant comorbid conditions like Hypertension, Diabetes Mellitus, Coronary artery disease for more than 5 years.
  • 4. Any other primary malignancy
  • 5. Abnormal Haemogram: a. Haemoglobin < 10gm/dl, b. Platelet count < 100000/ cmm, c. Total leucocyte count < 3000/cmm.
  • 6. Abnormal renal function test: a. Blood urea >50mg/dl, b. Serum creatinine >1.2mg/dl.

研究者

发起方
ONE

相似试验

Chemotherapy followed by radiotherapy response... | 临床试验